Freedom I’s Sponsor Sells Entire Interest to NextG Tech Limited
by Marlena Haddad on 2022-06-08 at 5:30pm

Freedom Acquisition I Corp. (NYSE:FACT.U) announced this afternoon that a former member of its sponsor, LVS III SPE XLIII LP, has sold its entire interest to NextG Tech Limited.

Freedom I, which included PIMCO in the sponsor group, still has nearly nine months left to find an acquisition with a deadline date of March 2, 2023. However, this is now the third SPAC in roughly a week’s time that has negotiated a new arrangement for its sponsor. This comes on the heels of Group Nine’s deal with the 890 5th team, and Tribe Capital Markets resigning from Tribe Capital Growth Corp. I’s sponsor group.

However, under the Freedom’s amended letter of agreement, LVS assigned all of its rights, interests and obligations to NextG. Additionally, the agreement permits Freedom I to pay China Bridge Capital (“CBC”), an affiliate of NextG, for certain advisory services pursuant the CBC Agreement.

In May 2021, the SPAC entered into an agreement with CBC for advisory and investment banking services in connection with a potential business combination. Under the CBC Agreement, Freedom I will pay CBC a customary advisory fee, which will be negotiated at the time of the business combination, upon closing.

Furthermore, Freedom I issued an unsecured promissory note in the amount of up to $500,000 to its sponsor. The proceeds of the note, which may be drawn down from time to time until, will be used for general working capital purposes. The note doesn’t bear interest and is payable in full before 24 months from the closing of the IPO or the consummation of the business combination.

Prior to the first payment of all or any portion of the principal balance of the note in cash, the payee has the option to convert all of the principal balance into private placement warrants, each warrant exercisable for one ordinary share at an exercise price of $1.50 per share. The terms of the warrants would be identical to those issued by Freedom I to the payee in a private placement that was consummated in connection with its IPO.

Freedom I priced its $300 million IPO on February 25, 2021 and aims to combine with a scalable fintech target with distinct business strengths and differentiations. The SPAC is led by Executive Chairman Tidjane Thiam and CEO Adam Gishen.

 

Freedom I’s Sponsor Sells Entire Interest to NextG Tech Limited
Recent Posts
by Nicholas Alan Clayton on 2025-07-01 at 7:51pm

Vendome Acquisition Corporation I (NASDAQ:VNMEU) announced the pricing of its $200 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “VNMEU”, Wednesday, July 2, 2025. The new SPAC plans to focus its search on target business in the consumer sector operating in North America, Southeast Asia, and Europe....

by Nicholas Alan Clayton on 2025-07-01 at 7:47pm

Origin Investment Corp. I (NASDAQ:ORIQU) announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ORIQU”, Wednesday, July 2, 2025. The new SPAC aims to mount a broad search for a target with a strong management and both revenue and earnings growth potential....

by Nicholas Alan Clayton on 2025-07-01 at 7:19pm

1RT Acquisition Corp. (NASDAQ:ONCHU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “ONCHU”, Wednesday, July 2, 2025. The new SPAC plans to target company in the digital asset ecosystem involved in the creation, storage, exchange or management of such assets, whether...

by Nicholas Alan Clayton on 2025-07-01 at 3:49pm

D. Boral ARC Acquisition II Corp. (NASDAQ:ARBCU) has filed for a $250 million SPAC to give underwriter D. Boral a second in-house SPAC to pursue deals with. The new SPAC offers investors a 1/2 warrant and an initial 18-month time frame to complete a deal. D. Boral II’s sponsor may automatically extend this once by...

by Nicholas Alan Clayton on 2025-07-01 at 11:33am

Ribbon (NASDAQ:RIBB) has entered into a definitive agreement to combine with Japanese biotech firm DRC Medicine at a pro forma equity value of $422 million. Tokyo-based DRC Medicine manufactures reusable anti-bacterial and anti-allergen wearables and aims to go deeper into the medical device and pharmaceutical space. Transaction Overview Ribbon is expected to provide $50.4 million...

logo

Copyright © 2025 SPACInsider, Inc. All Rights Reserved